Antonio Giannelli
Physician Assistant · Lansing, MINPI 1841369642
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 1,121 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $5,531 and has fallen 80.1% since, to $1,101 in 2025. Among physician assistant clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,121 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$5K
- Amgen$4K
- AbbVie$3K
- UCB, Inc.$2K
- AstraZeneca$2K
- Novartis$1K
- plus $5K from 28 others
What the payments were for
- Food & beverage$21,10798%
- Education$5382%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 366 | $4,574 |
| Amgen(2 entities) | 183 | $4,209 |
| AbbVie | 141 | $2,733 |
| UCB, Inc. | 85 | $2,424 |
| AstraZeneca(2 entities) | 63 | $1,572 |
| Novartis | 41 | $1,037 |
| Mallinckrodt Hospital Products Inc. | 36 | $845 |
| Lilly USA, LLC | 26 | $543 |
| Pfizer | 31 | $461 |
| ANI Pharmaceuticals, Inc. | 21 | $421 |
| Boehringer Ingelheim | 18 | $402 |
| Aurinia Pharma U.S., Inc. | 12 | $377 |
| E.r. Squibb & Sons, L.L.C. | 24 | $368 |
| Sanofi | 7 | $234 |
| GSK | 12 | $210 |
| Organon | 10 | $204 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $149 |
| Janssen Scientific Affairs, LLC | 2 | $140 |
| Fresenius Kabi USA, LLC | 6 | $123 |
| Genentech USA, Inc. | 8 | $116 |
| Merck | 3 | $74 |
| Sobi, Inc | 3 | $61 |
| Sandoz | 3 | $56 |
| Fidia Pharma USA Inc. | 3 | $56 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Kyowa Kirin, Inc. | 2 | $38 |
| United Therapeutics Corporation | 1 | $32 |
| Alvogen Inc | 2 | $30 |
| Boston Scientific | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Radius Health, Inc. | 1 | $15 |
| Hospira, Inc. | 1 | $14 |
| Bioventus LLC | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,645 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 115 | $853,100 |
| RinvoqUpadacitinib | 45 | $282,316 |
| OrenciaAbatacept | 51 | $278,782 |
| OtezlaApremilast | 47 | $219,604 |
| Enbrel MiniEtanercept | 22 | $188,312 |
| Xeljanz XrTofacitinib Citrate | 22 | $146,352 |
| Enbrel SureclickEtanercept | 18 | $139,675 |
| EnbrelEtanercept | 19 | $137,213 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 15 | $107,453 |
| Orencia ClickjectAbatacept | 14 | $100,507 |
| HumiraAdalimumab | 15 | $100,247 |
| KevzaraSarilumab | 17 | $72,495 |
| Hydroxychloroquine Sulfate | 633 | $45,375 |
| MethotrexateMethotrexate Sodium | 498 | $21,005 |
| RasuvoMethotrexate/Pf | 24 | $17,480 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira | $2,733 | $382,56360 claims |
| AmgenOtezla, Enbrel | $4,209 | $356,81766 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $368 | $278,78251 claims |
| SanofiKevzara | $234 | $72,49517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Lansing
- Lauren KaylorLansing$23K
- Kevin DuffyLansing$23K
- Timothy PalmerLansing$17K
- Sarang PatelRoyal Oak$660K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Taylor HennrickAdrian$430K
- Erin van DykeGrand Rapids$346K
- Ashley AldridgeAnn Arbor$298K
- Derek SusallaRochester Hills$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.